Through global partnerships, Cipher generates royalty revenue from three successful brands. In addition to offering healthcare professionals more products to help their patients with skin and other health conditions, the revenue from these brands supports our growing dermatology pipeline.
Absorica® is an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Cipher markets Absorica in the United States through our partnership with Sun Pharmaceuticals. In September 2014, Sun Pharmaceuticals began offering Absorica in 25 milligram and 35 milligram dosage strengths to give physicians greater flexibility in their dosing regimens. For full prescribing information, including further details about indication, contraindications, warnings and precautions, please consult the Absorica Prescribing Information.
ConZip® / Durela® is an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. Cipher markets the product as ConZip in the United States through our partnership with Vertical Pharmaceuticals, and Durela in Canada through our partnership with Medical Futures Inc., which has recently been acquired by Tribute Pharma.
Lipofen® is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides (TG) and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipofen is also indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Cipher markets Lipofen in the United States through our partnership with Kowa Pharmaceuticals America, Inc.